Doxofylline

**Presentation**
Brezofil® 200: Each tablet contains Doxofylline INN 200 mg.
Brezofil® 400: Each tablet contains Doxofylline INN 400 mg.
Brezofil® 400 SR: Each sustained release tablet contains Doxofylline INN 400 mg.
Brezofil® Syrup: Each 5 ml syrup contains Doxofylline INN 100 mg.

**Description**
Doxofylline is a new generation xanthine belonging to a new class of drug referred to as Novofylline, which is chemically 1,3-dimethyl-3,7-dihydro-purine-2,6-dione. Its molecular formula is C_{11}H_{14}N_{4}O_{4} and its molecular weight is 266.253 g/mol.

**Dosage & Administration**

<table>
<thead>
<tr>
<th>Total daily dose</th>
<th>Weight of the child</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 ml</td>
<td>10 kg</td>
</tr>
<tr>
<td>9 ml</td>
<td>15 kg</td>
</tr>
<tr>
<td>12 ml</td>
<td>20 kg</td>
</tr>
<tr>
<td>15 ml</td>
<td>25 kg</td>
</tr>
<tr>
<td>18 ml</td>
<td>30 kg</td>
</tr>
<tr>
<td>21 ml</td>
<td>35 kg</td>
</tr>
<tr>
<td>24 ml</td>
<td>40 kg</td>
</tr>
</tbody>
</table>

**Side-effects**
After xanthine administration, nausea, vomiting, epigastric pain, cephalalgia, irritability, insomnia, tachycardia, extrasystole, tachypnea and occasionally, hyperglycemia and albuminuria may occur. If a potential oral overdose is established, the patient may present with severe arrhythmias and seizures; these symptoms could be the first sign of an intoxication. Adverse reactions may cause the withdrawal from treatment, a lower dose rechallenge may start only after the advice of a physician.

**Contraindications**
This is contraindicated for individuals who have shown hypersensitivity to Doxofylline and its components. It is also contraindicated in patients with acute myocardial infarction, hypotension, and in lactating women.

**Drug Interactions**
Doxofylline should not be administered together with other xanthine derivatives. Toxic synergism with ephedrine has been documented for xanthines. Like other xanthines, Doxofylline should not be administered with other xanthine derivatives. Toxic reactions have been reported in case of overdosage of xanthine compounds. If a potential oral overdose is established, the patient may present with severe arrhythmias and seizure; these symptoms could be the first sign of an intoxication. Adverse reactions may cause the withdrawal from treatment, a lower dose rechallenge may start only after the advice of a physician.

**Use in Pregnancy & Lactation**
Animal reproduction studies indicate that Doxofylline does not cause fetal harm when administered to pregnant animals nor can affect reproduction capacity. However, since there is limited experience in human during pregnancy, xanthines should be given to a pregnant woman only if clearly needed.

**Storage**
1) Store at room temperature (not exceeding 30°C).
2) Store in cool and dry place, protected from light.

**Commercial Pack**
Brezofil® 200: Each box contains 3 blister strips of 10 tablets.
Brezofil® 400: Each box contains 3 blister strips of 10 tablets.
Brezofil® 400 SR: Each box contains 3 blister strips of 10 tablets.
Brezofil® Syrup: Each bottle contains 60 ml, 100 ml syrup and a measuring cup.